A BIA was performed comparing clinical cost offsets for rt-CGM compared with SMBG for U.S. Medicaid enrollees with type 1 diabetes (T1D) over one year. Clinical effects for HbA1c reduction using rt-CGM (-1.0%) and SMBG (-0.4%) were taken from the DIAMOND randomized controlled trial, converted into an economic benefit, and inflated ($U.S. 2019). Reduced hospitalization rates for severe hypoglycemia (SH; -73%) and diabetic ketoacidosis (DKA; -80%) were taken from the RESCUE trial, a Belgian observational cohort study, where SMBG was used in the year prior to countrywide rt-CGM reimbursement and outcomes tracked for one year. Estimated cost savings for HbA1c reduction (low and high), SH and DKA hospitalizations were taken from published literature and inflated ($U.S. 2019). We tested various ranges of pricing for rt-CGM and SMBG. Switching all U.S. Medicaid enrollees with T1D from SMBG to rt-CGM would result in an estimated 51,796 and 21,253 fewer SH and DKA hospitalizations, respectively, per year. Applying the clinical cost offsets against the added cost for rt-CGM over SMBG resulted in cost savings in most scenarios. Our modelling study demonstrates the substantial clinical and economic benefits using rt-CGM over SMBG in all U.S. Medicaid enrollees with T1D.


M.E. Minshall: Consultant; Self; Dexcom, Inc. J.J. Isitt: Employee; Self; Dexcom, Inc. C. Graham: Consultant; Self; Dexcom, Inc., DreaMed Diabetes. P.M. Lynch: Employee; Self; Dexcom, Inc. Stock/Shareholder; Self; Dexcom, Inc.


Dexcom, Inc.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.